



Frimley Clinical Commissioning Group

Thames Valley Priorities Committee Commissioning Policy Statement

Policy No. TVPC97 Immunotherapy for allergic rhinoconjunctivitis

**Recommendation made by
the Priorities Committee: January 2020**

Date of issue: November 2020

Due to the lack of good quality evidence of clinical and cost effectiveness compared with other pharmacological treatments, sublingual and subcutaneous immunotherapy such as Grazax® and Pollinex® are not normally funded for allergic rhinoconjunctivitis.

The management of severe allergic rhinoconjunctivitis requiring safe allergen immunotherapy is commissioned by NHS England.

NOTES:

- Potentially exceptional circumstances may be considered by a patient's CCG where there is evidence of significant health status impairment (e.g. inability to perform activities of daily living) and there is evidence that the intervention sought would improve the individual's health status.
- This policy will be reviewed in the light of new evidence or new national guidance, e.g. from NICE.
- Thames Valley clinical policies can be viewed at <http://www.fundingrequests.ccsu.nhs.uk/>